About Aridis Pharma
Aridis Pharma is a company based in San Jose (United States) founded in 2005 by Vu Truong. Aridis Pharma has raised $42.11 million across 14 funding rounds from investors including HHS, Cystic Fibrosis Foundation and SBIR. Aridis Pharma offers products and services including AR-301, AR-501, AR-320, and AR-701. Aridis Pharma operates in a competitive market with competitors including argenx, MacroGenics, Alexion, Zai Lab and Insmed, among others.
- Headquarter San Jose, United States
- Founders Vu Truong
- Stage Public
-
Sectors
Healthcare
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Aridis Pharmaceuticals Inc.
-
Annual Revenue
$3.09 M (USD)101.37as on Dec 31, 2022
-
Net Profit
-$30.37 M (USD)28.02as on Dec 31, 2022
-
EBITDA
-$29.51 M (USD)30.21as on Dec 31, 2022
-
Total Equity Funding
$42.11 M (USD)
in 14 rounds
-
Latest Funding Round
$4.85 M (USD), Post-IPO
Dec 20, 2022
-
Investors
HHS
& 3 more
-
Employee Count
Employee Count
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Aridis Pharma
Aridis Pharma is a publicly listed company on the OTC with ticker symbol ARDS in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of Aridis Pharma
Aridis Pharma offers a comprehensive portfolio of products and services, including AR-301, AR-501, AR-320, and AR-701.
Targets S. aureus alpha-toxin for pneumonia treatment
Inhalable therapy to starve bacteria in cystic fibrosis
Prevents S. aureus infections in ventilated patients
Neutralizes SARS-CoV-2 variants for COVID-19 treatment
People of Aridis Pharma
Unlock access to complete
Unlock access to complete
Funding Insights of Aridis Pharma
Aridis Pharma has successfully raised a total of $42.11M across 14 strategic funding rounds. The most recent funding activity was a Post-IPO round of $4.85 million completed in December 2022. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 14
- Last Round Post-IPO — $4.8M
-
First Round
First Round
(01 Dec 2006)
- Investors Count 4
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Dec, 2022 | Amount | Post-IPO - Aridis Pharma | Valuation |
investors |
|
| Oct, 2020 | Amount | Post-IPO - Aridis Pharma | Valuation |
investors |
|
| Jan, 2017 | Amount | Grant - Aridis Pharma | Valuation |
investors |
Investors in Aridis Pharma
Aridis Pharma has secured backing from 4 investors, including institutional investors. Prominent investors backing the company include HHS, Cystic Fibrosis Foundation and SBIR.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Research funding and support for cystic fibrosis patients are provided.
|
Founded Year | Domain | Location | |
|
Federal innovation and scientific achievement services are provided.
|
Founded Year | Domain | Location | |
|
Public health and human services are overseen by HHS.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Aridis Pharma
Financial Statements - Aridis Pharma
Aridis Pharma Comparisons
Competitors of Aridis Pharma
Aridis Pharma operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as argenx, MacroGenics, Alexion, Zai Lab and Insmed, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Antibody-based drugs are developed for autoimmune diseases and cancer treatment.
|
|
| domain | founded_year | HQ Location |
A biopharmaceutical company focused on cancer therapeutics development.
|
|
| domain | founded_year | HQ Location |
Therapies for rare and devastating diseases are developed by Alexion.
|
|
| domain | founded_year | HQ Location |
Antibody-based therapies for cancers and inflammatory diseases are developed.
|
|
| domain | founded_year | HQ Location |
Developer of small molecule inhibitors for rare lung diseases
|
|
| domain | founded_year | HQ Location |
Therapeutics for retinal diseases are developed by the company.
|
Frequently Asked Questions about Aridis Pharma
Aridis Pharma was founded in 2005 and raised its 1st funding round 1 year after it was founded.
Aridis Pharma is headquartered in San Jose, United States. It is registered at San Jose, California, United States.
Vu Truong is the current CEO of Aridis Pharma. They have also founded this company.
Aridis Pharma is a funded company, having raised a total of $42.11M across 14 funding rounds to date.
Annual revenue of Aridis Pharma is $3.09M as on Dec 31, 2022.
Provider of human monoclonal antibodies against infectious diseases. The companys lead human antibodies candidates are against hospital-acquired pneumonia, ventilator-associated pneumonia, and cystic fibrosis. The companys products target infectious diseases, including nosocomial infections, cystic fibrosis, and severe wound infections. In addition, it offers mAb discovery technology platform that enables the recovery of rare, naturally occurring protective antibodies generated by the human immune system.
Aridis Pharma's top competitors include argenx, Zai Lab and Kodiak Sciences.
Aridis Pharma offers AR-301, AR-501, AR-320, and AR-701.
Yes, Aridis Pharma is publicly traded on OTC under the ticker symbol ARDS.
Aridis Pharma has 4 investors. Key investors include HHS, Cystic Fibrosis Foundation, SBIR, and Military Health.
The ticker symbol of Aridis Pharma is ARDS on OTC.